Do FETO CDH survivors need the same follow-up program as non-FETO patients?

Autor: Pertierra Cortada A; Neonatology Department, BCNatal, Barcelona Center for Maternal Fetal and Neonatal Medicine Hospital Sant Joan de Déu and Hospital Clínic, Institut de Recerca Sant Joan de Déu University of Barcelona, Passeig Sant Joan de Déu, 2. 08950, Esplugues de Llobregat, Barcelona, Spain. africa.pertierra@sjd.es., Clotet Caba J; Neonatology Department, BCNatal, Barcelona Center for Maternal Fetal and Neonatal Medicine Hospital Sant Joan de Déu and Hospital Clínic, Institut de Recerca Sant Joan de Déu University of Barcelona, Passeig Sant Joan de Déu, 2. 08950, Esplugues de Llobregat, Barcelona, Spain., Hadley S; Boston Children's Hospital, Boston, MA, USA., Sabrià Bach J; Fetal Medicine Unit, BCNatal, Barcelona Center for Maternal Fetal and Neonatal Medicine Hospital Sant Joan de Déu and Hospital Clínic, University of Barcelona, Barcelona, Spain.; Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin (RICORS), Instituto de Salud Carlos III, Madrid, Spain., Iriondo Sanz M; Neonatology Department, BCNatal, Barcelona Center for Maternal Fetal and Neonatal Medicine Hospital Sant Joan de Déu and Hospital Clínic, Institut de Recerca Sant Joan de Déu University of Barcelona, Passeig Sant Joan de Déu, 2. 08950, Esplugues de Llobregat, Barcelona, Spain., Camprubí Camprubí M; Neonatology Department, BCNatal, Barcelona Center for Maternal Fetal and Neonatal Medicine Hospital Sant Joan de Déu and Hospital Clínic, Institut de Recerca Sant Joan de Déu University of Barcelona, Passeig Sant Joan de Déu, 2. 08950, Esplugues de Llobregat, Barcelona, Spain.
Jazyk: angličtina
Zdroj: European journal of pediatrics [Eur J Pediatr] 2023 Jul; Vol. 182 (7), pp. 3243-3255. Date of Electronic Publication: 2023 May 05.
DOI: 10.1007/s00431-023-04977-3
Abstrakt: Congenital diaphragmatic hernia (CDH) survivors are at risk of developing significant chronic health conditions and disabilities. The main purpose of this study was to compare the outcomes of CDH infants at 2 years of age (2y) according to whether the infants had undergone fetoscopic tracheal occlusion (FETO) during the prenatal period and characterize the relationship between morbidity at 2y and perinatal characteristics. Retrospective cohort single center study. Eleven years of clinical follow-up data (from 2006 to 2017) were collected. Prenatal and neonatal factors as well as growth, respiratory, and neurological evaluations at 2y were analyzed. One hundred and fourteen CDH survivors were evaluated. Failure to thrive (FTT) was present in 24.6% of patients, gastroesophageal reflux disease (GERD) in 22.8%, 28.9% developed respiratory problems, and 22% had neurodevelopment disabilities. Prematurity and birth weight < 2500 g were related to FTT and respiratory morbidity. Time to reach full enteral nutrition and prenatal severity markers seemed to influence all outcomes, but FETO therapy itself only had an effect on respiratory morbidity. Some variables related to postnatal severity (ECMO, patch closure, days on mechanic ventilation, and vasodilator treatment) were associated with almost all outcomes.  Conclusion: CDH patients have specific morbidities at 2y, most of them related to lung hypoplasia severity. Only respiratory problems were related to FETO therapy itself. The implementation of a specific multidisciplinary follow-up program for CDH patients is essential to provide them the best standard of care, but, more severe patients, regardless of whether they received prenatal therapy, need a more intensive follow-up. What is Known: • Antenatal fetoscopic endoluminal tracheal occlusion (FETO) increases survival in more severe congenital diaphragmatic hernia patients. • Congenital diaphragmatic hernia survivors are at risk of developing significant chronic health conditions and disabilities. Very limited data are available about the follow-up in patients with congenital diaphragmatic hernia and FETO therapy. What is New: • CDH patients have specific morbidities at 2 years of age, most of them related to lung hypoplasia severity. • FETO patients present more respiratory problems at 2 years of age but they don't have an increased incidence of other morbidities. More severe patients, regardless of whether they received prenatal therapy, need a more intensive follow-up.
(© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje